strontium-89 chloride (Metastron)

Indications

• used in the treatment of painful bony metastases
  • preferentially targets metabolically active regions of bone

Dosage

• intravenous:
  • 10.9-22.6 mg, Water for Injection q.s. to 1 mL
  • 1 mCi/mL
• a repeat dose can be administered at 3-month intervals if necessary

Pharmacokinetics

• bone pain relief is generally seen within 7-21 days & sustained for 3-6 months

More general terms

• strontium chloride
• radiopharmaceutical

Components

• strontium-89